Tag Archives: Adamis Pharma

A Director at Adamis Pharma (NASDAQ: ADMP) is Buying Shares

Today, a Director at Adamis Pharma (ADMP – Research Report), William Denby, bought shares of ADMP for $9,937. Following this transaction William Denby’s holding in the company was increased by 6.1% to a total of $163.1K. In addition to William

What Did This CEO Just Do with Personal Shares of Adamis Pharma (NASDAQ: ADMP)?

Today, the President & CEO of Adamis Pharma (ADMP – Research Report), Dennis Phd Carlo, sold shares of ADMP for $30.04K. In addition to Dennis Phd Carlo, 2 other ADMP executives reported Sell trades in the last month. See today’s

Adamis Pharma (ADMP) Gets a Hold Rating from B.Riley FBR

B.Riley FBR analyst Andrew D’silva reiterated a Hold rating on Adamis Pharma (ADMP – Research Report) today and set a price target of $2.50. The company’s shares opened today at $2.39, close to its 52-week low of $2.01. D’silva wrote:

Maxim Group Reaffirms Their Buy Rating on Adamis Pharma (ADMP)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $13. The company’s shares opened today at $3.90. McCarthy noted: “Adamis announced FDA approval of Symjepi Jr. (15 mg)

Adamis Pharma (ADMP) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP) today and set a price target of $13. The company’s shares opened today at $3. McCarthy noted: “The PDUFA date for Symjepi jr. (0.15mg) is approaching

H.C. Wainwright Thinks Adamis Pharma’s Stock is Going to Recover

In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Adamis Pharma (NASDAQ: ADMP). The company’s shares closed yesterday at $2.75, close to its 52-week low of $2.20. Kolbert commented: “EpiPen as an Exchange NASDAQ